NCT07043283View on ClinicalTrials.gov

A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Healthy Male Chinese Subjects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Healthy Subjects
Interventions
DRUG

Ebronucimab

Ebronucimab subcutaneous injection.

Trial Locations (1)

Unknown

Zhejiang Xiaoshan Hospital, Hangzhou

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY